Applied Therapeutics, Inc.
APLT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | 0.00 | 0.01 | -0.00 |
| FCF Yield | -20.90% | -45.06% | -40.45% | -16.30% |
| EV / EBITDA | -4.16 | -0.75 | -0.89 | -1.30 |
| Quality | ||||
| ROIC | -864.26% | -112.74% | -64.84% | -55.22% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.97 | 0.95 | 1.31 | -0.44 |
| Growth | ||||
| Revenue 3-Year CAGR | -54.56% | -77.46% | -70.78% | 769,600.23% |
| Free Cash Flow Growth | 9.54% | 28.97% | -47.09% | 16.55% |
| Safety | ||||
| Net Debt / EBITDA | 0.50 | 1.20 | 1.89 | 2.33 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -4,013.67 | -4,212.69 | -4,987.13 |